The Government while reviewing FDI policy on pharma sector has put in place necessary safeguards by providing that non-compete clause would not be permitted. This will enable Indian promoters to operate in the same line of business in new ventures. Further, to ensure domestic availability of essential medicines and drugs; and to maintain deployment of adequate capital in R&D, extant FDI policy on the sector mandates specified level of production of National List of Essential Medicine drugs and extent of R&D expenditure to be maintained by the investee company.
Both Greenfield and Brownfield investments are in line with the initiative of 'Make in India' and thus there is no proposal under consideration of Government to restrict such investments only to Greenfield project.
Powered by Capital Market - Live News